Corient Private Wealth LP Purchases Shares of 159,262 Artivion, Inc. $AORT

Corient Private Wealth LP acquired a new position in shares of Artivion, Inc. (NYSE:AORT) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 159,262 shares of the company’s stock, valued at approximately $3,579,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Bank of America Corp DE acquired a new position in shares of Artivion in the second quarter valued at $11,717,000. Freestone Grove Partners LP bought a new position in Artivion in the second quarter worth $328,000. Jupiter Topco LLC acquired a new stake in Artivion during the second quarter worth $384,000. Parkman Healthcare Partners LLC acquired a new stake in Artivion during the second quarter worth $3,122,000. Finally, Legal & General Group Plc bought a new stake in Artivion in the 2nd quarter valued at $5,826,000. 86.37% of the stock is currently owned by institutional investors.

Artivion Price Performance

Shares of Artivion stock opened at $27.04 on Wednesday. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -386.23 and a beta of 1.25. The firm’s 50-day moving average price is $25.90 and its two-hundred day moving average price is $29.41. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The company had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. On average, equities analysts predict that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Citigroup restated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Needham & Company LLC reissued a “buy” rating and issued a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Canaccord Genuity Group increased their price target on shares of Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Wall Street Zen cut shares of Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Stifel Nicolaus set a $45.00 price objective on Artivion in a report on Monday, June 1st. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Jean F. Holloway sold 977 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares of the company’s stock, valued at approximately $5,245,521.82. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the sale, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. The trade was a 42.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 114,978 shares of company stock worth $2,965,155. 6.30% of the stock is currently owned by insiders.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.